Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and... see more

Recent & Breaking News (NDAQ:AZN)

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

Business Wire September 18, 2021

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial

Business Wire September 17, 2021

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

GlobeNewswire September 17, 2021

IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer

Business Wire September 17, 2021

IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

Business Wire September 9, 2021

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials

Business Wire September 9, 2021

FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season

Business Wire August 31, 2021

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

Business Wire August 20, 2021

ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2

Business Wire August 9, 2021

SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus

Business Wire August 2, 2021

BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older

Business Wire July 23, 2021

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

GlobeNewswire July 13, 2021

EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration

GlobeNewswire July 9, 2021

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors

GlobeNewswire July 8, 2021

Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma

Business Wire July 8, 2021

Phase III pivotal trial of once weekly exenatide in adolescents aged 10-17 shows benefit for the treatment of type 2 diabetes

Business Wire June 25, 2021

PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021

PR Newswire June 8, 2021

CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting

Business Wire June 7, 2021

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years

Business Wire June 4, 2021

LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial

Business Wire June 3, 2021